Inhibición del Sistema inmunológico en el cáncer por el receptor PD-1

Introduction: In the area of cáncer research, immune control point inhibitors are taking great importance as cáncer treatments. PD-1 protein is involved in the process of immune evasión of malignant cells, improving tumor cell growth and promoting apoptosis in T cells. Interactions between PD-1 and its ligands play a key immunoregulatory role in activation. and tolerance of T lymphocytes, so this document investigated the current existence of certain drugs that have certain mechanisms related to the activity of this protein and its biomedical importance as a treatment in this pathology. Development: A search was conducted with the objective of elucidating the current State of research on PD-1 protein and its therapeutic involvement in cáncer. Different studies and clinical triáis were consulted through the NCBI and Clinical Triáis and Orange Book platforms. Conclusión: An exponential increase was observed in biomedical research publications ofPDl-Cáncer from 2009 to a máximum peak in 2018 but a decrease after this. Related clinical triáis have been carried out during phase 1, and Nivolumab and Pembrolizumab among others are among the commercially available drugs.